Ionis provides third quarter financial results and improved 2019 guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. CSCO
9. KTOS
10. NVDA

Go back to Ionis provides third quarter financial results and improved 2019 guidance

Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 50c, Revenues Beat; Raises FY19 Revenue Guidance Above Consensus

November 6, 2019 7:21 AM EST

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of $0.18, $0.50 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $168 million versus the consensus estimate of $153.8 million.

"Our commitment to innovation and to advancing our antisense technology has enabled us to produce a broad pipeline of potentially transformational medicines for patients with rare and common diseases. Our commercial medicines, SPINRAZA, TEGSEDI and WAYLIVRA, are important examples of the life-changing potential of our pipeline. In early October, we licensed AKCEA-ANGPTL3-LRx to... More